Rajesh Vashist, SiTime CEO, sells $579.5k in SITM stock

Investing.comTuesday, November 4, 2025 at 11:32:09 PM
Rajesh Vashist, SiTime CEO, sells $579.5k in SITM stock
Rajesh Vashist, the CEO of SiTime, has sold $579.5k worth of SITM stock. This transaction is part of the normal course of business for executives managing their portfolios.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Intapp Q1 FY26 presentation slides: Cloud growth accelerates despite stock slump
PositiveFinancial Markets
Intapp's Q1 FY26 presentation highlights impressive cloud growth, showcasing resilience despite recent stock challenges. The company is making significant strides in expanding its cloud services, indicating a strong future outlook.
Lumentum Q1 FY26 slides: revenue surges 58% YoY, stock dips despite beat
PositiveFinancial Markets
Lumentum has reported an impressive 58% year-over-year revenue surge for Q1 FY26, showcasing strong performance despite a dip in stock prices. This growth highlights the company's robust market position and potential for future success.
AMD Q3 2025 slides reveal 36% revenue surge, stock falls on future growth concerns
NegativeFinancial Markets
AMD reported a remarkable 36% surge in revenue for Q3 2025, showcasing strong performance. However, despite this impressive growth, the company's stock has fallen due to concerns about future growth prospects, leaving investors cautious.
Earnings call transcript: Flywire Q3 2025 beats forecasts, stock rises
PositiveFinancial Markets
Flywire's Q3 2025 earnings call revealed results that exceeded forecasts, leading to a rise in their stock price. This positive performance highlights the company's strong financial health and growth potential.
Earnings call transcript: Synchronoss' Q3 2025 sees modest stock uptick
PositiveFinancial Markets
Synchronoss reported a modest uptick in stock during its Q3 2025 earnings call, reflecting positive growth and investor confidence. The company highlighted key achievements and future strategies that contributed to this encouraging performance.
Earnings call transcript: Coupang Q3 2025 beats earnings forecast, stock dips
NeutralFinancial Markets
Coupang's Q3 2025 earnings call revealed that the company exceeded earnings forecasts, although its stock experienced a dip following the announcement. Investors are analyzing the results to gauge future performance.
Earnings call transcript: Lumentum Q1 2026 beats EPS forecast, stock dips
NeutralFinancial Markets
Lumentum's Q1 2026 earnings call revealed that the company beat EPS forecasts, although its stock experienced a dip following the announcement. Investors are analyzing the results to gauge future performance.
Earnings call transcript: Rivian Q3 2025 reports narrower EPS loss, stock slides
NegativeFinancial Markets
Rivian's Q3 2025 earnings call revealed a narrower EPS loss than expected, but the stock still slid in response. Investors are reacting cautiously to the news, reflecting ongoing concerns about the company's financial performance and market position.
Latest from Financial Markets
Private-Credit Earnings Ease Investor Concern Over Asset Class’s Health
PositiveFinancial Markets
Apollo CEO Marc Rowan has reassured investors by addressing concerns regarding the health of the private-credit asset class, easing worries and highlighting the stability of the sector.
Private-Credit Earnings Ease Investor Concern Over Asset Class’s Health
PositiveFinancial Markets
Apollo CEO Marc Rowan has reassured investors by addressing concerns regarding the health of the private-credit asset class, easing worries and highlighting the sector's resilience.
Aviat Networks Q1 FY2026 slides: Revenue jumps 21.4%, exceeding expectations
PositiveFinancial Markets
Aviat Networks reported a remarkable 21.4% increase in revenue for Q1 FY2026, surpassing market expectations. This growth highlights the company's strong performance and positive outlook in the telecommunications sector.
Stoke Therapeutics Q3 2025 presentation: strong revenue growth amid clinical progress
PositiveFinancial Markets
Stoke Therapeutics recently presented its Q3 2025 results, showcasing impressive revenue growth alongside significant advancements in its clinical programs. The company's progress highlights its commitment to developing innovative therapies, making it a key player in the biotechnology sector.
Amgen Q3 2025 slides: Revenue up 12%, guidance raised on strong product performance
PositiveFinancial Markets
Amgen has reported a 12% increase in revenue for Q3 2025, prompting the company to raise its guidance due to strong product performance. This positive trend highlights the effectiveness of their strategies and the growing demand for their offerings.
Corsair Q3 2025 slides show strong growth amid missed earnings forecasts
NeutralFinancial Markets
Corsair's Q3 2025 slides indicate a strong growth trajectory, despite missing earnings forecasts. The company is navigating challenges while showcasing resilience in its performance.